Loading...
Market
Story
Johnson & Johnson's Rybrevant Shows Positive Results, 49% Response Rate in Lung and Colorectal Cancer
Sep 14, 2024, 01:48 PM
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy has shown a positive overall survival trend compared to chemotherapy alone in patients with previously treated EGFR-mutated lung cancer. Additionally, the combination therapy demonstrated a 49 percent overall response rate in metastatic colorectal cancer. The Phase II data from Rybrevant in colorectal cancer suggest that bispecifics may outperform standard monoclonal antibodies, potentially ushering in curative potential. However, the Mariposa-2 combo was described as a 'toxic & expensive arrow' by a #ESMO24 discussant.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%